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BACKGROUND
Data are lacking on the long-term effect on cardiovascular events of adding sita-
gliptin, a dipeptidyl peptidase 4 inhibitor, to usual care in patients with type 2 
diabetes and cardiovascular disease.
METHODS
In this randomized, double-blind study, we assigned 14,671 patients to add either 
sitagliptin or placebo to their existing therapy. Open-label use of antihyperglyce-
mic therapy was encouraged as required, aimed at reaching individually appropri-
ate glycemic targets in all patients. To determine whether sitagliptin was noninfe-
rior to placebo, we used a relative risk of 1.3 as the marginal upper boundary. The 
primary cardiovascular outcome was a composite of cardiovascular death, nonfatal 
myocardial infarction, nonfatal stroke, or hospitalization for unstable angina.
RESULTS
During a median follow-up of 3.0 years, there was a small difference in glycated 
hemoglobin levels (least-squares mean difference for sitagliptin vs. placebo, 
−0.29 percentage points; 95% confidence interval [CI], −0.32 to −0.27). Overall, 
the primary outcome occurred in 839 patients in the sitagliptin group (11.4%; 
4.06 per 100 person-years) and 851 patients in the placebo group (11.6%; 4.17 per 
100 person-years). Sitagliptin was noninferior to placebo for the primary compos-
ite cardiovascular outcome (hazard ratio, 0.98; 95% CI, 0.88 to 1.09; P<0.001). 
Rates of hospitalization for heart failure did not differ between the two groups 
(hazard ratio, 1.00; 95% CI, 0.83 to 1.20; P = 0.98). There were no significant 
between-group differences in rates of acute pancreatitis (P = 0.07) or pancreatic 
cancer (P = 0.32).
CONCLUSIONS
Among patients with type 2 diabetes and established cardiovascular disease, adding 
sitagliptin to usual care did not appear to increase the risk of major adverse car-
diovascular events, hospitalization for heart failure, or other adverse events. 
(Funded by Merck Sharp & Dohme; TECOS ClinicalTrials.gov number, NCT00790205.)
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Good glycemic control among pa-tients with type 2 diabetes reduces the risk of diabetes-related microvascular 
complications.1-3 Many antihyperglycemic agents 
are licensed for the treatment of type 2 diabetes, 
but questions regarding the long-term cardio-
vascular safety of some of these agents have 
been raised.4,5 International regulatory agencies 
have responded by requiring that new antihyper-
glycemic agents not only show glucose-lowering 
ability but also are not associated with clinically 
meaningful increases in rates of major adverse 
cardiovascular events.6,7
Sitagliptin, an orally administered dipeptidyl 
peptidase 4 (DPP-4) inhibitor, prolongs the ac-
tion of incretin hormones, including glucagon-
like peptide 1 and glucose-dependent insulino-
tropic polypeptide, by inhibiting their breakdown. 
This improves glycemic control in patients with 
type 2 diabetes, primarily by suppressing gluca-
gon levels and increasing endogenous insulin 
secretion.8 Two previous cardiovascular outcome 
trials of other DPP-4 inhibitors did not show an 
increase or decrease in the number of major 
adverse cardiovascular events but did raise safety 
concerns regarding a possible elevated risk of 
hospitalization for heart failure,9,10 with meta-
analyses of randomized, controlled trials sug-
gesting an increase of 24 to 25% in such a risk 
associated with these agents.11,12
In the Trial Evaluating Cardiovascular Out-
comes with Sitagliptin (TECOS), we assessed the 
long-term cardiovascular safety of adding sita-
gliptin to usual care, as compared with usual 
care alone, in patients with type 2 diabetes and 
established cardiovascular disease.
Me thods
Study Oversight
We conducted this randomized, double-blind, 
placebo-controlled, event-driven trial at 673 sites 
in 38 countries on the basis of a design and ra-
tionale that have been reported previously.13 The 
study was designed and run independently by 
the Duke Clinical Research Institute (DCRI) and 
the University of Oxford Diabetes Trials Unit 
(DTU) in an academic collaboration with the 
sponsor, Merck Sharp & Dohme. The trial orga-
nization, participating countries, and a list of 
investigators are provided in Supplementary Ap-
pendix 1, available with the full text of this ar-
ticle at NEJM.org. The protocol was approved by 
the ethics committee at each participating trial 
site. All analyses were performed by DCRI and 
DTU independent of the sponsor and according 
to the prespecified statistical analysis plan. The 
first and second authors wrote the first draft of 
the manuscript. Executive committee members 
and coauthors from DCRI, DTU, and the spon-
sor reviewed the data, revised the manuscript, 
and assume responsibility for trial adherence to 
the protocol and the accuracy and completeness 
of the data and the analyses. The protocol is also 
available at NEJM.org.
Study Population
Eligible patients had type 2 diabetes with estab-
lished cardiovascular disease and were at least 
50 years of age, with a glycated hemoglobin 
level of 6.5 to 8.0% when treated with stable 
doses of one or two oral antihyperglycemic 
agents (metformin, pioglitazone, or sulfonylurea) 
or insulin (with or without metformin). Estab-
lished cardiovascular disease was defined as a 
history of major coronary artery disease, ischemic 
cerebrovascular disease, or atherosclerotic periph-
eral arterial disease. Patients were excluded if they 
had taken a DPP-4 inhibitor, glucagon-like pep-
tide-1 receptor agonist, or thiazolidinedione (other 
than pioglitazone) during the preceding 3 months; 
if they had a history of two or more episodes of 
severe hypoglycemia (defined as requiring third-
party assistance) during the preceding 12 months; 
or if the estimated glomerular filtration rate 
(eGFR) was less than 30 ml per minute per 1.73 m2 
of body-surface area at baseline. All enrolled 
patients provided written informed consent.
Randomization and Study Medication
Patients were randomly assigned in a 1:1 ratio to 
receive either sitagliptin at a dose of 100 mg 
daily (or 50 mg daily if the baseline eGFR was 
≥30 and <50 ml per minute per 1.73 m2) or 
matching placebo. An interactive voice-response 
system assigned the study medication in a dou-
ble-blind manner, blocked within each site. This 
regimen was continued throughout the follow-
up period, with predefined dose adjustments for 
changes in the eGFR.13 Patients who had two or 
more episodes of severe hypoglycemia between 
study visits, despite adjustment of other antihyper-
glycemic agents, were required to discontinue 
the study medication.
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The glycated hemoglobin level was measured 
locally at enrollment, at 4 and 8 months, and 
then annually. All other laboratory values of in-
terest were collected opportunistically from usu-
al-care data. Since sitagliptin lowers the glucose 
level, patients in the sitagliptin group would be 
expected to have lower glycated hemoglobin 
levels than those in the placebo group initially. 
During the study, the use of open-label antihy-
perglycemic agents was encouraged as required, 
with the aim of achieving individually appropri-
ate glycated hemoglobin targets in all patients. 
This approach was taken to permit the assess-
ment of possible drug-specific effects by mini-
mizing potential confounding effects of differ-
ential glucose control. All the patients were 
followed until study closeout whenever possible, 
regardless of whether they were taking a study 
medication.
Outcomes
The primary composite cardiovascular outcome 
was defined as the first confirmed event of car-
diovascular death, nonfatal myocardial infarc-
tion, nonfatal stroke, or hospitalization for un-
stable angina. The secondary composite 
cardiovascular outcome was the first confirmed 
event of cardiovascular death, nonfatal myocar-
dial infarction, or nonfatal stroke.
Other secondary outcomes included the oc-
currence of the individual components of the 
primary composite cardiovascular outcome, fa-
tal and nonfatal myocardial infarction, fatal and 
nonfatal stroke, death from any cause, and hos-
pitalization for heart failure. Additional pre-
specified outcomes included changes in the 
glycated hemoglobin level and the eGFR, initia-
tion of additional antihyperglycemic agents or 
long-term insulin therapy, and frequency of se-
vere hypoglycemia. An independent clinical-
events classification committee whose members 
were unaware of study-group assignments adju-
dicated all events of death, myocardial infarc-
tion, stroke, hospitalization for unstable angina, 
hospitalization for heart failure, acute pancreati-
tis, and cancers (other than nonmelanoma skin 
cancers). All outcome definitions are provided in 
Supplementary Appendix 1. Adjudicated event 
definitions are listed in the Clinical Events Clas-
sification Committee Charter, which is available 
in Supplementary Appendix 2 at NEJM.org.
During the trial period, prespecified events of 
clinical interest that were collected systemati-
cally (including cardiovascular events), severe 
hypoglycemia, and expected diabetes-related 
complications were not reported as adverse 
events. Other serious adverse events were col-
lected and reported according to regulatory re-
quirements. Data regarding nonserious adverse 
events that were not part of prespecified out-
comes were not collected.
Statistical Analysis
We assessed the primary noninferiority hypoth-
esis by determining whether the upper boundary 
of the two-sided 95% confidence interval of the 
hazard ratio for the risk of the primary compos-
ite cardiovascular outcome did not exceed 1.30 
in the sitagliptin group, as compared with the 
placebo group, in the per-protocol population, 
with a key supporting analysis in the intention-
to-treat population. The statistical analysis plan 
prespecified that the following hypotheses be 
tested in a sequential manner: noninferiority for 
the primary composite cardiovascular outcome 
(main analysis, per-protocol; supporting analy-
sis, intention-to-treat), noninferiority for the 
secondary composite cardiovascular outcome in 
the per-protocol analysis, superiority for the pri-
mary composite cardiovascular outcome in the 
intention-to-treat analysis, and superiority for 
the secondary composite cardiovascular out-
come in the intention-to-treat analysis. We used 
the Cox proportional-hazards model to calculate 
hazard ratios and two-sided 95% confidence 
intervals, stratified according to region. For this 
analysis, data from all patients were censored on 
the date they were last known to be free of the 
components of the primary composite cardio-
vascular outcome. We performed sensitivity 
analyses to assess the effect of missing data on 
study results on the basis of inverse weighting of 
the probability of dropout.14
We calculated that 611 patients with a con-
firmed primary composite cardiovascular out-
come would provide a power of 90% for the test 
of noninferiority (hazard ratio, 1.00). For superi-
ority, we calculated that 1300 patients with a 
primary composite cardiovascular outcome 
would provide a power of approximately 81% to 
determine the superiority of sitagliptin over pla-
cebo (hazard ratio, 0.85). Assuming an annual 
rate of 2.5 to 3.0% for the primary composite 
cardiovascular outcome, we determined that the 
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randomization of approximately 14,000 patients 
with a 6-year study period in total would yield at 
least 1300 patients with the primary composite 
cardiovascular outcome.
We summarized the baseline characteristics 
of the patients using means (±SD) or medians 
and interquartile ranges. Prespecified subgroups 
were analyzed on the basis of the previous type 
of oral antihyperglycemic agent received, previ-
ous insulin use, race, geographic region, sex, 
age at randomization, glycated hemoglobin lev-
el, duration of diabetes, body-mass index, renal 
function, smoking status, history of hyperten-
sion, blood pressure, previous heart failure, and 
use of antihypertensive agents, statins, or aspi-
rin.
We performed additional analyses of the first 
hospitalization for heart failure and the compos-
ite of hospitalization for heart failure or cardio-
vascular death in both the per-protocol and in-
tention-to-treat populations, with methods 
analogous to those used for the analysis of the 
primary composite cardiovascular outcome. Fur-
ther details regarding the statistical analysis 
plan, including the definition of the per-protocol 
population, are provided in the study protocol. 
All analyses were conducted with the use of SAS 
software, version 9.0 or higher (SAS Institute).
R esult s
Study Patients
A total of 14,735 patients underwent randomiza-
tion from December 2008 through July 2012. Of 
these patients, 14,671 were included in the inten-
tion-to-treat population, with 7332 assigned to 
receive sitagliptin and 7339 assigned to receive 
placebo (Fig. 1). The study was closed in March 
2015, after the requisite minimum of 1300 pa-
tients were confirmed to have had a primary 
composite outcome. Median follow-up was 3.0 
years (interquartile range, 2.3 to 3.8; maximum, 
5.7). Overall, 95.1% of patients in the sitagliptin 
group and 94.1% of those in the placebo group 
completed the study, with 26.1% and 27.5% of all 
study patients, respectively, discontinuing study 
medication prematurely. Vital status was ob-
tained for 97.5% of patients (Fig. 1). The charac-
teristics of the patients at baseline were well 
balanced between the study groups with respect 
to demographic characteristics and the use of 
antihyperglycemic agents and secondary cardio-
vascular prevention medications (Table S1 in 
Supplementary Appendix 1). At baseline, the 
mean (±SD) glycated hemoglobin level was 
7.2±0.5%, and patients had been living with dia-
betes for a mean of 11.6±8.1 years.
Glycemic Control
At 4 months, the mean glycated hemoglobin 
values were 0.4 percentage points lower in the 
sitagliptin group than in the placebo group. This 
difference narrowed during the study period, 
with an overall least-squares mean difference of 
−0.29% in the sitagliptin group (95% confidence 
interval [CI], −0.32 to −0.27) (Fig. 2). Patients in 
the sitagliptin group received fewer additional 
antihyperglycemic agents than did those in the 
placebo group during the study period (1591 vs. 
2046 patients; hazard ratio, 0.72; 95% CI, 0.68 
to 0.77; P<0.001) and were less likely to start 
long-term insulin therapy (542 vs. 744 patients; 
hazard ratio, 0.70; 95% CI, 0.63 to 0.79; P<0.001) 
(Table S2 in Supplementary Appendix 1).
Primary and Secondary Composite 
Cardiovascular Outcomes
Overall in the intention-to-treat population, the 
primary composite cardiovascular outcome oc-
curred in 839 patients in the sitagliptin group 
(11.4%, 4.06 per 100 person-years) and 851 in 
the placebo group (11.6%, 4.17 per 100 person-
years). There was no significant between-group 
difference in the primary composite cardiovas-
cular outcome (hazard ratio in the per-protocol 
analysis, 0.98; 95% CI, 0.88 to 1.09; P<0.001 for 
noninferiority; hazard ratio in the intention-to-
treat analysis, 0.98; 95% CI, 0.89 to 1.08; P = 0.65 
for superiority) or in the secondary composite 
cardiovascular outcome (hazard ratio in the per-
protocol analysis, 0.99; 95% CI, 0.89 to 1.11; 
P<0.001 for noninferiority; hazard ratio in the 
intention-to-treat analysis, 0.99; 95% CI, 0.89 to 
1.10; P = 0.84 for superiority) (Table 1 and Fig. 3A 
and 3B). Results from all sensitivity analyses 
were consistent with the findings in the main 
analyses. (All cardiovascular outcomes in the 
per-protocol analysis are provided in Table S3 in 
Supplementary Appendix 1.)
Other Secondary Outcomes
There was no significant difference in the rate of 
hospitalization for heart failure, which was re-
ported in 228 patients in the sitagliptin group 
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(3.1%; 1.07 per 100 person-years) and 229 in the 
placebo group (3.1%; 1.09 per 100 person-years) 
(hazard ratio in the intention-to-treat analysis, 
1.00; 95% CI, 0.83 to 1.20; P = 0.98). The com-
posite outcome of hospitalization for heart fail-
ure or cardiovascular death occurred in 538 pa-
tients in the sitagliptin group (7.3%; 2.54 per 
100 person-years) and 525 in the placebo group 
(7.2%; 2.50 per 100 person-years) (hazard ratio 
in the intention-to-treat analysis, 1.02; 95% CI, 
0.90 to 1.15; P = 0.74). Death from any cause oc-
curred in 547 patients in the sitagliptin group 
(7.5%; 2.48 per 100 person-years) and 537 in the 
placebo group (7.3%; 2.45 per 100 person-years) 
Figure 1. Enrollment, Follow-up, and Vital Status.
GCP denotes Good Clinical Practice guidelines.
14,671 Were included in the
intention-to-treat population
14,735 Patients underwent randomization
64 Were excluded from all analyses
11 Did not provide consent
53 Had GCP deviations (at 1 site)
7332 Were assigned to receive sitagliptin
66 Did not receive sitagliptin
7339 Were assigned to receive placebo
65 Did not receive placebo
434 (5.9%) Did not complete the study
14 (0.2%) Had primary end point
before discontinuation of the
study
3 Were lost to follow-up
11 Withdrew consent
12 Discontinued the drug
prematurely
420 (5.7%) Did not have primary end 
point before discontinuation
of the study
68 Were lost to follow-up
352 Withdrew consent
302 Discontinued the drug
prematurely
6972 (95.1%) Completed
the study
1650 Discontinued drug
prematurely
6905 (94.1%) Completed
the study
1706 Discontinued drug
prematurely
360 (4.9%) Did not complete the study
12 (0.2%) Had primary end point
before discontinuation of the
study
12 Withdrew consent
10 Discontinued the drug
prematurely
348 (4.7%) Did not have primary end 
point before discontinuation
of the study
61 Were lost to follow-up
287 Withdrew consent
251 Discontinued the drug
prematurely
Vital status among those who did not
complete the study 
Lost to follow-up
2 Died
27 Were found surviving on 
or after May 5, 2014
32 Were not found
Withdrawal of consent
22 Died
157 Were found surviving on
or after May 5, 2014
120 Were not found
Vital status among those who did not
complete the study 
Lost to follow-up
1 Died
32 Were found surviving on 
or after May 5, 2014
38 Were not found
Withdrawal of consent
20 Died
165 Were found surviving on
or after May 5, 2014
178 Were not found
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(hazard ratio in the intention-to-treat analysis, 
1.01; 95% CI, 0.90 to 1.14; P = 0.88) (Table 1 and 
Fig. 3C and 3D).
Subgroup Analyses
The results of subgroup analyses of major pre-
specified primary cardiovascular outcomes are 
provided in Figure S1 in Supplementary Appen-
dix 1. No significant interactions were observed 
apart from body-mass index.
Safety Outcomes
There was no significant difference between the 
sitagliptin group and the placebo group with 
respect to the overall incidence of infections, 
cancer, site-reported renal failure, or severe hy-
poglycemia. In the two study groups, patients 
who had at least one severe hypoglycemic epi-
sode had a longer mean duration of diabetes and 
were more often taking insulin. Confirmed 
acute pancreatitis events were uncommon over-
all but numerically more frequent in the sita-
gliptin group (23 events [0.3%]) than in the 
placebo group (12 events [0.2%]) (P = 0.07 in the 
intention-to-treat analysis and P = 0.12 in the 
per-protocol analysis) (Table S4 in Supplemen-
tary Appendix 1). Confirmed pancreatic cancers 
were also uncommon overall but numerically 
less frequent in the sitagliptin group (9 events 
[0.1%]) than in the placebo group (14 events 
[0.2%]) (P = 0.32 in the intention-to-treat analysis 
and P = 0.85 in the per-protocol analysis) (Ta-
ble 1).
The rate of death from noncardiovascular 
causes was 2.3% in the two study groups, with 
no notable differences in individual causes. 
Rates of death from infection were 0.6% and 
0.7% in the sitagliptin group and the placebo 
group, respectively. No clinically relevant differ-
ences in the incidence of additional clinical 
events of interest or serious adverse events were 
noted (Table 2, and Table S5 in Supplementary 
Appendix 1).
At 48 months, the mean change from base-
line in the eGFR was greater in the sitagliptin 
group than in the placebo group (−4.0±18.4 and 
−2.8±18.3 ml per minute per 1.73 m2, respec-
tively). The slightly lower eGFR in the sitagliptin 
group remained consistent over all post-random-
ization visits, with an estimated least-squares 
mean difference of −1.34 ml per minute per 1.73 
m2 (95% CI, −1.76 to −0.91; P<0.001).
Discussion
In our global clinical trial, which was performed 
in a usual-care setting among patients with type 
2 diabetes and established cardiovascular dis-
Figure 2. Glycated Hemoglobin Level.
Data are shown as mean values. The I bars indicate standard deviations.
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Outcome Sitagliptin Placebo
Hazard Ratio 
(95% CI) P Value
no. (%)
no. per 100 
 person-yr no. (%)
no. per 100 
person-yr
Per-protocol analysis
No. of patients in analysis 7257 7266
Cardiovascular outcome
Cardiovascular death, nonfatal myo-
cardial infarction, nonfatal 
stroke, or hospitalization for 
unstable angina: primary com-
posite outcome
695 (9.6) 3.73 695 (9.6) 3.82 0.98 (0.88–1.09) <0.001*
Cardiovascular death, nonfatal myo-
cardial infarction, or nonfatal 
stroke: secondary composite 
outcome
609 (8.4) 3.24 602 (8.3) 3.28 0.99 (0.89–1.11) <0.001*
Noncardiovascular outcome
Acute pancreatitis 20 (0.3) 0.10 11 (0.2) 0.06 1.80 (0.86–3.76) 0.12
Charter-defined cancer 248 (3.4) 1.30 260 (3.6) 1.40 0.93 (0.78–1.10) 0.38
Pancreatic cancer 9 (0.1) 0.05 10 (0.1) 0.05 0.91 (0.37–2.25) 0.85
Severe hypoglycemia 144 (2.0) 0.77 125 (1.7) 0.68 1.13 (0.89–1.44) 0.31
Intention-to-treat analysis
No. of patients in analysis 7332 7339
Cardiovascular outcome
Cardiovascular death, nonfatal myo-
cardial infarction, nonfatal 
stroke, or hospitalization for 
unstable angina: primary com-
posite outcome
839 (11.4) 4.06 851 (11.6) 4.17 0.98 (0.89–1.08) 0.65
Cardiovascular death 311 (4.2) 291 (4.0)
Nonfatal myocardial infarction 275 (3.8) 286 (3.9)
Nonfatal stroke 145 (2.0) 157 (2.1)
Hospitalization for unstable 
 angina
108 (1.5) 117 (1.6)
Cardiovascular death, nonfatal myo-
cardial infarction, or nonfatal 
stroke: secondary composite 
outcome
745 (10.2) 3.58 746 (10.2) 3.62 0.99 (0.89–1.10) 0.84
Cardiovascular death 313 (4.3) 293 (4.0)
Nonfatal myocardial infarction 285 (3.9) 294 (4.0)
Nonfatal stroke 147 (2.0) 159 (2.2)
Secondary outcome
Cardiovascular death 380 (5.2) 1.72 366 (5.0) 1.67 1.03 (0.89–1.19) 0.71
Hospitalization for unstable 
 angina
116 (1.6) 0.54 129 (1.8) 0.61 0.90 (0.70–1.16) 0.42
Fatal or nonfatal myocardial 
 infarction
300 (4.1) 1.42 316 (4.3) 1.51 0.95 (0.81–1.11) 0.49
Fatal or nonfatal stroke 178 (2.4) 0.83 183 (2.5) 0.87 0.97 (0.79–1.19) 0.76
Death from any cause 547 (7.5) 2.48 537 (7.3) 2.45 1.01 (0.90–1.14) 0.88
Hospitalization for heart failure† 228 (3.1) 1.07 229 (3.1) 1.09 1.00 (0.83–1.20) 0.98
Table 1. Rates of Composite Cardiovascular Outcomes and Key Secondary Outcomes.
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ease, we found that the addition of sitagliptin to 
usual care among patients with glycemic equi-
poise did not affect rates of major atheroscle-
rotic cardiovascular events. Sitagliptin therapy 
did not change rates of death from any cause, 
cardiovascular death, or noncardiovascular 
death, and there were no notable differences 
between the groups with regard to specific 
causes of death, including infection.
Sitagliptin therapy was not associated with 
changes in rates of hospitalization for heart 
failure (hazard ratio, 1.00), as has been sug-
gested in trials of other DPP-4 inhibitors.9,10 
There were also no between-group differences in 
the rate of the composite outcome of hospital-
ization for heart failure or cardiovascular death.
No significant increase in the rate of severe 
hypoglycemia was seen among patients in the 
sitagliptin group, as compared with the placebo 
group. Fewer patients in the sitagliptin group 
required the use of additional antihyperglycemic 
agents or initiated long-term insulin therapy 
during the study period.
Concern has been raised about a possible as-
sociation between incretin-based therapies and 
adverse pancreatic effects.15 Although acute pan-
creatitis was uncommon, it occurred more often 
in the sitagliptin group, but the difference was 
not significant. Pancreatic cancer was also un-
common and occurred more often in the place-
bo group, but again the difference was not sig-
nificant.
The observation that sitagliptin therapy was 
not associated with a change in long-term rates 
of cardiovascular events is consistent with the 
findings from shorter-term outcome trials of 
other DPP-4 inhibitors, including saxagliptin 
and alogliptin. The Saxagliptin Assessment of 
Vascular Outcomes Recorded in Patients with 
Diabetes Mellitus–Thrombolysis in Myocardial 
Infarction 53 (SAVOR-TIMI 53) trial and the Ex-
amination of Cardiovascular Outcomes with 
Alogliptin versus Standard of Care (EXAMINE) 
trial both showed that these agents did not in-
crease or decrease the number of major adverse 
cardiovascular events.9,10 However, results from 
the SAVOR-TIMI 53 trial showed an unexpected 
excess rate of hospitalization for heart failure in 
the saxagliptin group (hazard ratio, 1.27; 95% 
CI, 1.07 to 1.51).8 The EXAMINE trial showed a 
nonsignificant numerical imbalance in hospital-
ization for heart failure in the alogliptin group 
as compared with placebo (hazard ratio, 1.19; 
95% CI, 0.90 to 1.58) but no imbalance in a post 
hoc analysis of the composite of hospitalization 
for heart failure or cardiovascular death.16 In 
contrast, in our trial we found that rates of hos-
pitalization for heart failure did not differ be-
tween the two groups. The reasons for the lack 
of a heart-failure safety signal in our trial as 
compared with previous trials of DPP-4 agents 
may relate to differences in the patients who 
were enrolled, in the background care that was 
provided, or in the recording and definition of 
heart-failure events, or to intrinsic pharmaco-
logic differences among DPP-4 inhibitors, or it 
may simply represent the play of chance in previ-
ous findings.
Outcome Sitagliptin Placebo
Hazard Ratio 
(95% CI) P Value
no. (%)
no. per 100 
 person-yr no. (%)
no. per 100 
person-yr
Hospitalization for heart failure or 
cardiovascular death†
538 (7.3) 2.54 525 (7.2) 2.50 1.02 (0.90–1.15) 0.74
Noncardiovascular outcome
Acute pancreatitis 23 (0.3) 0.11 12 (0.2) 0.06 1.93 (0.96–3.88) 0.07
Charter-defined cancer 268 (3.7) 1.25 290 (4.0) 1.37 0.91 (0.77–1.08) 0.27
Pancreatic cancer 9 (0.1) 0.04 14 (0.2) 0.07 0.66 (0.28–1.51) 0.32
Severe hypoglycemia 160 (2.2) 0.78 143 (1.9) 0.70 1.12 (0.89–1.40) 0.33
*  The P value is for the noninferiority of sitagliptin, as compared with placebo, which was calculated by determining whether the upper 
boundary of the two-sided 95% confidence interval of the hazard ratio exceeded 1.30. All other listed P values are based on the Wald statis-
tic from a Cox model stratified according to region with a test of differences in hazard ratios.
†  The analyses of hospitalization for heart failure were adjusted for a history of heart failure at baseline.
Table 1. (Continued.)
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Our study was designed, run, and analyzed 
exclusively by the DCRI and the University of Ox-
ford DTU, and only members of the data and 
safety monitoring board had access to unblinded 
outcome or efficacy data before the database lock. 
Our study was adequately powered, with greater-
than-anticipated event rates for the primary com-
posite cardiovascular outcome, and had a longer 
follow-up than previous outcome studies of DPP-4 
inhibitors. The population that we studied had 
well-managed cardiovascular and glycemic risk fac-
tors at baseline and was broadly similar to those 
studied in the SAVOR-TIMI 53 and EXAMINE 
trials.17 The results of our study would appear to 
have wide-ranging generalizability, given that it 
was carried out in a usual-care setting and in-
cluded patients with a global distribution. There 
was uniform ascertainment and adjudication of 
hospitalization for heart failure, acute pancreati-
tis, and pancreatic cancer, with an aim of ensur-
ing the integrity of the safety data.
Our study has certain limitations. We enrolled 
patients with moderate hyperglycemia (glycated 
hemoglobin level, 6.5 to 8.0%) and excluded 
those with severe renal insufficiency. Potential 
biases are the possible confounding effects on 
cardiovascular outcomes by the small residual 
between-group difference in the glycated hemo-
globin level and the greater use of antihypergly-
cemic agents in the placebo group. The opportu-
nistic approach to data collection, apart from 
the selected values for glycated hemoglobin, re-
sulted in limited acquisition of data regarding 
the ratio of urinary albumin to creatinine.
Our study results showed that sitagliptin may 
be used in a diverse group of patients with type 
2 diabetes who are at high cardiovascular risk 
without increasing rates of cardiovascular com-
plications, but these results cannot exclude pos-
sible benefits or risks with longer durations of 
therapy or in patients with more complicated 
coexisting illnesses. In our trial involving pa-
tients with type 2 diabetes and established car-
diovascular disease, the addition of sitagliptin to 
usual care did not have a significant effect on 
rates of major adverse cardiovascular events or 
hospitalization for heart failure.
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